跳至主要内容
临床试验/JPRN-UMIN000022440
JPRN-UMIN000022440招募中未知

Clinical trials for the safety and efficacy of the combination of XELOX,the colorectal cancer radical resection adjuvant chemotherapy and of chronic hepatitis therapeutic agent 3 oxygelmillpropionic acid polymer.(Phase 1 test) - Seroshion test (adjuvant chemotherapy)

Osaka University Hospital0 个研究点目标入组 5 人开始时间: 2016年6月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients who could not resect curatively. 2) Patients with active double cancer. 3) Patients with severe drug hypersensitivity, or with a history of drug allergy. 4) Patients with serious complications (heart failure, renal failure, liver failure, bleeding ulcer, watery diarrhea, intestinal paralysis, intestinal obstruction, severe diabetes). 5)Patients of cirrhosis with jaundice or of suspected cirrhosis of the liver. 6)Patients with the history of chronic hepatitis B and with the experience of Seroshion. 7)Patients with active infection. 8)Women with the possibility of pregnancy,during pregnancy,with the hope of pregnancy,or with breast-feeding. 9)Patients with mental severe disorder. 10)Other cases who doctor determines that patients are unsuitable for safely carrying out the present study.

研究者

相似试验